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Background: Osteoarthritis affecting the first metatarsophalangeal joint of the foot is a common condition which
results in pain, stiffness and impaired ambulation. Footwear modifications and foot orthoses are widely used in
clinical practice to treat this condition, but their effectiveness has not been rigorously evaluated. This article
describes the design of a randomised trial comparing the effectiveness of rocker-sole footwear and individualised
prefabricated foot orthoses in reducing pain associated with first metatarsophalangeal joint osteoarthritis.
Methods: Eighty people with first metatarsophalangeal joint osteoarthritis will be randomly allocated to receive
either a pair of rocker-sole shoes (MBT® Matwa, Masai Barefoot Technology, Switzerland) or a pair of individualised,
prefabricated foot orthoses (Vasyli Customs, Vasyli Medical™, Queensland, Australia). At baseline, the biomechanical
effects of the interventions will be examined using a wireless wearable sensor motion analysis system (LEGSys™,
BioSensics, Boston, MA, USA) and an in-shoe plantar pressure system (Pedar®, Novel GmbH, Munich, Germany). The
primary outcome measure will be the pain subscale of the Foot Health Status Questionnaire (FHSQ), measured at
baseline and 4, 8 and 12 weeks. Secondary outcome measures will include the function, footwear and general foot
health subscales of the FHSQ, severity of pain and stiffness at the first metatarsophalangeal joint (measured using
100 mm visual analog scales), global change in symptoms (using a 15-point Likert scale), health status (using the
Short-Form-12® Version 2.0 questionnaire), use of rescue medication and co-interventions to relieve pain, the
frequency and type of self-reported adverse events and physical activity levels (using the Incidental and Planned
Activity Questionnaire). Data will be analysed using the intention to treat principle.
Discussion: This study is the first randomised trial to compare the effectiveness of rocker-sole footwear and individualised
prefabricated foot orthoses in reducing pain associated with osteoarthritis of the first metatarsophalangeal joint,
and only the third randomised trial ever conducted for this condition. The study has been pragmatically designed
to ensure that the findings can be implemented into clinical practice if the interventions are found to be effective, and
the baseline biomechanical analysis will provide useful insights into their mechanism of action.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12613001245785* Correspondence: h.menz@latrobe.edu.au
1Lower Extremity and Gait Studies Program, Faculty of Health Sciences, La
Trobe University, Bundoora 3086, Victoria, Australia
2Department of Podiatry, Faculty of Health Sciences, La Trobe University,
Bundoora 3086, Victoria, Australia
Full list of author information is available at the end of the article
© 2014 Menz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Menz et al. BMC Musculoskeletal Disorders 2014, 15:86 Page 2 of 13
http://www.biomedcentral.com/1471-2474/15/86Background
Osteoarthritis (OA) is the leading cause of chronic pain
and disability in Australia. In 2013, it was estimated that
1.9 million people in Australia had OA, and that this figure
is expected to increase to 3 million people by 2032 [1]. Al-
though the knee is the most commonly affected lower limb
region, foot involvement is also common. The most com-
monly affected region of the foot is the first metatarsopha-
langeal joint (MTPJ), with radiographic changes evident
in 12 to 35% of people aged over 35 years [2]. The
population prevalence of symptomatic radiographic
first MTPJ OA (i.e. both radiographic changes and as-
sociated symptoms) in people aged over 50 years has
recently been estimated as 7.8%, with a higher preva-
lence observed in women, older people, and those from
lower socio-economic classes [3].
People with first MTPJ OA typically present with
symptoms of pain and stiffness in their big toe joint that
increase with activity. Because the first MTPJ plays an
important role in the transfer of the body during the
propulsive phase of gait, people with first MTPJ OA will
often adopt an apropulsive walking pattern with a short-
ened step length and longer stance phase duration [4],
accompanied by excessive knee and hip flexion or hip
circumduction to assist the transfer of the swing limb
[5] and decreased loading of the first MTPJ [6]. In our
recently completed comparison of 43 cases and 43 con-
trols, we found that symptomatic first MTPJ OA was as-
sociated with a statistically significant reduction in all
subscales of the Foot Health Status Questionnaire and
the physical function and subscale of the Medical Out-
comes Study Short Form 36 questionnaire [7]. In
addition, Abhishek et al. have reported that great toe
pain is associated with lower scores on the health satis-
faction and psychological domains of the World Health
Organization Quality of Life questionnaire [8], and a re-
cent population-based study found that 72% of people
with symptomatic first MTPJ OA report disabling symp-
toms [3].
Many patients with first MTPJ OA seek surgical treat-
ment for their condition. A clinical audit of 785 cases of
foot surgery in Australia between July 1995 and June 1996
revealed surgery for this condition to be the fourth most
common procedure performed [9]. Similarly, a population-
based study of 6,956 inpatients in Sweden [10] indicated
that these procedures accounted for 15% of all foot and
ankle procedures. Our recent analysis of the Medicare Ben-
efits Schedule database indicated that between 1997 and
2006, over 46,000 private sector surgical procedures for
treatment of first MTPJ disorders (hallux valgus and hallux
rigidus) were subsidised under Medicare, at a direct cost of
approximately $2 M per year [11]. These costs, however,
are an underestimate of the total economic impact of the
condition. The 2013 Deloitte Access Economics analysisindicated that treatment expenses for OA accounted for
only 17% of the total cost of the disease, the remaining
costs being attributed to burden of disease and productivity
losses [1].
The aetiology of first MTPJ OA is not fully under-
stood. Increased age, previous trauma, family history
and a flat foot are commonly reported as contributing
factors in the literature, but few studies have been
undertaken to examine this in detail [5]. There is, how-
ever, evidence that certain structural characteristics of
the foot are more common in those with first MTPJ OA
compared to controls. Our recent systematic review con-
cluded that people with first MTPJ OA were more likely
to exhibit a dorsiflexed first metatarsal relative to the
second metatarsal, a plantarflexed forefoot on the rear-
foot, reduced first MTPJ joint range of motion, a longer
proximal phalanx, distal phalanx, medial and lateral ses-
amoids, and a wider first metatarsal and proximal phal-
anx [12]. Although temporal relationships cannot be
inferred from such studies, it has been hypothesised that
as a result of this altered foot structure, the first metatarsal
is less able to plantarflex during propulsion to allow the
proximal phalanx to dorsally rotate on the first metatarsal
head, resulting in dorsal joint compression of the first
MTPJ. Over time, this process results in cartilage damage,
exposure of subchondral bone, juxta-articular sclerosis,
and the formation of a dorsal osteophyte [5].
Conservative treatment of first MTPJ OA involves mea-
sures to obtain pain relief (including anti-inflammatory
medications and intra-articular injections), physical ther-
apy to maintain range of motion, and footwear and foot
orthoses to modify foot function. Surgical management
may involve removal of the dorsal exostosis, insertion of a
joint implant, or, in advanced cases, fusion of the first
MTPJ [13]. However, despite the high prevalence of first
MTPJ OA and its impact on quality of life, very few of
these treatments have been rigorously evaluated. Further-
more, in patients with more advanced disease, post-
surgical complications such as transfer lesions, forefoot
pain, malunion and interphalangeal OA are common [14].
Our recent systematic review of interventions for first
MTPJ OA [15] revealed only one low quality randomised
trial evaluating the effectiveness of two different physical
therapy programs in 20 participants [16]. Following the
publication of this review, we completed a randomised
controlled trial which found that intra-articular visco-
supplementation (hylan G-F20) was no more effective
than a placebo (sterile saline) for this condition [17].
Clearly, there is a need for additional well-designed tri-
als into non-surgical interventions for the treatment of
first MTPJ OA.
The pain associated with first MTPJ OA generally oc-
curs during the propulsive phase of gait when the prox-
imal phalanx is compressed against the dorsal osteophyte
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need for the first MTPJ to dorsiflex has the potential to re-
duce joint compression and alleviate pain when walking.
Clinically, this can be achieved using a footwear modifica-
tion known as a rocker-sole, in which the sole of the shoe
is curved (at the forefoot, rearfoot, or both) [18]. The aim
of this modification is to allow the body’s centre of mass
to “roll over” the base of support, reducing the need for
foot and ankle dorsiflexion and subsequently decreasing
the loads placed on the forefoot. Biomechanical studies
have confirmed this proposed mechanism, indicating that
rocker-sole shoes reduce sagittal plane motion of the fore-
foot [19] and ankle [19-22], reduce forefoot plantar pres-
sures [22,23] and reduce first MTPJ dorsiflexion [24] when
walking. Such a change in biomechanics may be therapeut-
ically beneficial in those with first MTPJ OA by reducing
compression at the first MTPJ. Although no controlled
studies have been performed, uncontrolled reports suggest
that rocker-sole shoes are effective in the management of
first MTPJ pain, and may in some cases prevent the need
for surgery [14,25,26].
In both clinical practice and research, the main barrier
to the use of therapeutic footwear is concern regarding
aesthetics, and indeed, adherence to therapeutic foot-
wear in people with diabetes or rheumatoid arthritis has
been reported to be as low as 22% [27-29]. However, the
recent popularity of so-called “physiological” or “toning”
footwear, pioneered by the Swiss company Masai Bare-
foot Technology (MBT), has made the rocker-sole shoe
more fashionable. It is therefore likely that acceptability
and adherence to this intervention will be much greater
than that associated with the relatively unattractive medical
grade footwear that has been used for this purpose previ-
ously. Indeed, a recent trial of MBT shoes for knee OA re-
ported a drop-out rate of only 2% over 12 weeks [30].
In addition to rocker-sole shoes, first MTPJ OA is
often managed with prefabricated or customised foot
orthoses. Foot orthoses are thought to decrease pain
associated with this condition by allowing the first
metatarsal to achieve sufficient plantarflexion in prep-
aration for propulsion, thereby minimising joint com-
pression [31]. Although widely used and recommended
in clinical practice guidelines [32], evidence to support
the effectiveness of this approach is limited to case re-
ports [26,33,34] and one recent case series study, which
demonstrated a clinically significant reduction in pain
over 24 weeks in 32 participants [35].
Given the prevalence and impact of first MTPJ OA, the
lack of evidence for existing interventions, and the prelim-
inary biomechanical and anecdotal evidence supporting
the use of rocker-sole shoes and prefabricated foot orth-
oses, there is a need to conduct a rigorous randomised
trial to evaluate which of these non-invasive treatments is
most effective.Methods
The trial has been registered on the Australian New
Zealand Clinical Trials Registry (ACTRN12613001245785).
Ethical approval
The La Trobe University Human Ethics Committee has
provided ethical approval (number 13–003). All partici-
pants will provide written informed consent prior to en-
rolment. Ethical standards will adhere to the National
Health and Medical Research Council (NHMRC) National
Statement [36] and the World Medical Association's
Declaration of Helsinki [37]. Publications associated
with the trial will be reported according to the Consolidated
Standards of Reporting Trials (CONSORT) 2010 State-
ment [38,39].
Design
The study design is a parallel-group randomised trial
with 12 week follow-up (see Figure 1), comparing two in-
terventions: commercially available rocker-sole footwear
(MBT® Matwa, Masai Barefoot Technology, Switzerland)
versus prefabricated foot orthoses (Vasyli Customs, Vasyli
Medical™, Queensland, Australia). The study has been
designed using the principles described by Osteoarth-
ritis Research Society International Clinical Trials Task
Force guidelines [40]. Permuted block randomisation with
random block sizes, stratified by sex, will be undertaken
using an interactive voice response telephone service pro-
vided by the NHMRC Clinical Trials Centre at the Univer-
sity of Sydney, New South Wales, Australia to ensure
allocation concealment. Participants will be informed that
they will receive either the rocker-sole footwear or the
foot orthoses (i.e. they will not be blinded to their group
allocation). Due to the nature of the intervention, research
staff administering the treatments cannot be blinded to
group allocation. However, follow-up assessment of out-
come measures will be via self-completion questionnaires
returned by mail, and those entering outcome measure
data and conducting statistical analyses will be blinded.
Participant recruitment, screening and eligibility criteria
To be included in the study, participants must:
(i) be aged at least 18 years;
(ii) report having pain in the first MTPJ on most days
for at least 12 weeks;
(iii) report having pain rated at least 20 mm on a
100 mm visual analogue scale (VAS);
(iv) have less than 64 degrees of dorsiflexion range of
motion of the first MTPJ [41];
(v) have pain upon palpation of the dorsal aspect of
the first MTPJ;
(vi) be able to walk household distances (>50 meters)
without the aid of a walker, crutches or cane;
Figure 1 Trial profile.
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La Trobe University (Melbourne, Victoria) on two
occasions and have their foot x-rayed;
(viii) be willing to not receive additional interventions
(such as physical therapy, foot orthoses, shoe
modifications, intra-articular injections, or sur-
gery) for the first MTPJ pain during the course of
the study;
(ix) be willing to discontinue taking all medications to
relieve pain at their first MTPJ (analgesics and non-
steroidal anti-inflammatory medications [NSAIDs],
except paracetamol up to 4 g/day) for at least 14 days
prior to the baseline assessment and during the
study period. Participants who do take paracetamol
for first MTPJ pain need to discontinue its use at
least 24 hours prior to the baseline assessment and
follow-up assessments at 4, 8 and 12 weeks.Exclusion criteria for participants in this study will be:
(i) pregnancy;
(ii) previous surgery on the first MTPJ;
(iii) significant deformity of the first MTPJ including
hallux valgus (grade of 3 or 4 scored using the
Manchester Scale) [42,43];
(iv) presence of one or more conditions within the foot
or ankle, in the opinion of the investigators, could
confound pain and functional assessments of the
first MTPJ, such as metatarsalgia, plantar fasciitis,
pre-dislocation syndrome, Achilles tendinopathy,
degenerative joint disease (other than the first
MTPJ);
(v) presence of any systemic inflammatory condition,
such as inflammatory arthritis, rheumatoid
arthritis, ankylosing spondylitis, psoriatic arthritis,
Figure 2 MBT® Matwa footwear.
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gout or any other connective tissue disease;
(vi) any medical condition that, in the opinion of the
investigators, makes the participant unsuitable for
inclusion (e.g., severe progressive chronic disease,
malignancy, clinically important pain in a part of
the musculoskeletal system other than the first
MTPJ, or fibromyalgia);
(vii) cognitive impairment (defined as a score of <7 on the
Short Portable Mental Status Questionnaire) [44];
(viii) intra-articular injections into the first MTPJ in the
previous 6 months;
(ix) currently wearing contoured foot orthoses
(although flat insoles will be permitted);
(x) currently wearing specialised footwear (footwear
that has been custom-made or ‘prescribed’ by a
health-care practitioner);
(xi) currently wearing shoes that would not be able to
accommodate a foot orthosis, or;
(xii) older people with a history of recurrent falls
(defined as 2 or more falls in the previous
12 months), as there is some evidence that rocker-
sole shoes may have short-term detrimental ef-
fects on balance [45].
Participants will be recruited by advertisements placed
in local newspapers, magazines, and social media, by
posters placed in healthcare facilities, senior citizens’
centres, retirement villages and mail-out advertisements
to health care practitioners in Melbourne. Although the
recruitment strategy will focus on older people (due to
their increased prevalence of OA), our inclusion criteria
are not restricted to those aged over 65 years, as in our
recently completed RCT of visco-supplementation for
first MTPJ OA [17], the age range of participants with
first MTPJ pain and radiographically confirmed first
MTPJ OA was 22 to 81 years, with a mean age of
54 years, indicating that the condition is also prevalent
in younger and middle-aged people.
Rocker-sole footwear group
The rocker-sole footwear group will be provided with a
pair of appropriately-sized rocker-sole shoes (MBT®
Matwa, Masai Barefoot Technology, Switzerland). This
shoe is characterised by a rounded sole in the antero-
posterior direction and a soft cushioned heel. Across the
full size range, the radius of curvature of the MBT is on
average 33 cm overall, 18 cm at the forefoot, 43 cm at
the midfoot, and 11 cm at the heel [46]. See Figure 2.
Prefabricated foot orthoses group
The prefabricated foot orthoses group will receive a pair
of foot orthoses (Vasyli Customs – medium density,
Vasyli Medical, Queensland, Australia) that will bemodified using a similar approach to that described by
Welsh et al. [35]. All orthoses will be full-length, but
modified by adding a first ray cut-out and trimming the
distal edge to the level of the 2nd to 5th toe sulci. In par-
ticipants with pronated feet, full length 4-degree medial
(varus) wedges (Formthotics, Foot Science International,
Christchurch, New Zealand) will be applied to the under-
side of the foot orthoses (see section on the Foot Posture
Index below). Those who do not have pronated feet will
have open cell polyurethane foam applied to the plantar
aspect of the rearfoot. See Figure 3.
Baseline assessments
Demographic factors, major medical conditions, health-
related quality of life and anthropometrics
Demographic factors (such as age, sex, education and in-
come), major medical conditions and number of medica-
tions currently prescribed, will be obtained via a structured
questionnaire. Height and weight will be measured using a
stadiometer and digital scales, respectively, and body mass
index will be calculated as weight (kg)/height (m)2. In
addition, two questionnaires will be included at baseline
as potential predictors of treatment outcome: the Pain
Catastrophizing Scale, a questionnaire containing 13 items
reflecting elevated negative cognitive responses to pain
[47], and relevant questions from the Monitor Orthopaedic
Shoes questionnaire [48], which assesses participants’ ex-
pectations of footwear-related interventions. Footwear will
also be assessed using selected items from the Footwear
Assessment Tool [49].
Clinical assessment of first MTPJ OA features
The following clinical observations will be used to char-
acterise the clinical features of first MTPJ OA in the
sample. The reliability of these observations has been re-
ported in detail previously (kappa values from 0.41 to
1.00 [41]).
(i) dorsal exostosis: the presence of a definite dorsal
bony exostosis will be determined via visual
observation of the first MTPJ;
Figure 3 Prefabricated foot orthoses to be used in the trial. Top: plantar surface of left foot orthosis. Bottom: dorsal surface of right foot orthosis.
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dorsal, dorso-medial and dorso-lateral regions
will be determined using manual palpation. An
effusion will be classified as present if the area is
compressible and displacement of fluid noted;
(iii) pain during motion: the examiner will grasp the
proximal phalanx of the hallux and dorsiflex the
digit until movement is no longer possible. This
process will be repeated 5 times with a positive test
result concluded if end range of motion produces
pain in at least 2 of the test trials;
(iv) hard end-feel: the examiner will grasp the proximal
phalanx and dorsiflex the hallux until movement is
no longer possible. A positive test result will be
documented if a hard osseous end-feel is determined
as opposed to a gradual end-feel of joint motion [50];
(v) crepitus during dorsiflexion: the examiner will apply
a compressive force while moving the joint through
its full range of dorsiflexion motion. This process
will be repeated 5 times with a positive test result
documented if a grating or cracking sensation
occurs during at least 2 of the test trials [51];
(vi) first MTPJ dorsiflexion range of motion: the passive,
non-weightbearing, dorsiflexion range of motion of
the first MTPJ will be measured in accordance to the
procedure described by Hopson et al. [52]. The first
metatarsal and proximal phalanx of the hallux will
initially be bisected in the sagittal plane. A
dorsiflexion force will be applied to the hallux untilend range of motion is reached, allowing the first ray
to maximally plantarflex. The angle between the
two lines will then be measured via a hand held goni-
ometer. This measurement technique has been
shown to be highly reliable in people with first MTPJ
pain (intra-class correlation coefficient of 0.95 [41]).
The assessment will be performed twice and the
average score will be documented.
Foot Posture Index (FPI)
To help determine the amount of rearfoot control to be
added to the orthoses in the prefabricated foot orthoses
group, the FPI will be documented. The FPI is a valid
and reliable clinical assessment tool [53] which consists
of six specific criteria: talar head palpation, supralateral
and infralateral malleolar curvature, calcaneal frontal
plane position, prominence in the region of the talonavi-
cular joint, medial arch height and abduction and adduc-
tion of the forefoot on the rearfoot. Each FPI criterion is
scored on a 5-point scale (range, −2 to +2). The six
scores obtained are then summated to give an overall
score of foot posture. The summated score has the po-
tential to range from −12 (highly supinated) to +12 (highly
pronated). The normal FPI (defined as ± 1 standard devi-
ation from the mean) has been reported to be +1 to +7
[54]. Therefore, participants who score greater than 7 will
be deemed to have pronated foot posture, and will have
full length medial wedges applied to the plantar aspect of
the foot orthoses. The magnitude of the wedge angulation
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of at least 2 points [35]. Those with an FPI score less than
7 will have open cell polyurethane foam applied to the
plantar aspect of the rearfoot.
Three-dimensional foot scanning
The FotoScan 3D foot scanner (Precision 3D Ltd, Weston-
super-mare, UK) will be used to obtain fully weight bearing
scans of both feet. Participants will be instructed to stand
relaxed with their feet approximately shoulder width apart
and their hands clasped lightly in front of them or gently
resting on the support rail if required. The FotoScan 3D de-
vice uses a fixed system of cameras and projectors to obtain
digital images of the foot, which are then automatically
converted to 3D models. According to the manufacturer,
the scans obtained with this system are accurate to within
less than half a millimetre.
Radiographic assessment of OA
The presence of radiographic OA will not be an inclu-
sion criterion, as in clinical practice, footwear interven-
tions are often provided on the basis of clinical findings
without confirmation of radiographic changes. However,
to document the radiographic severity of OA, weight-
bearing dorso-plantar and lateral radiographic projec-
tions will be obtained from the most symptomatic foot
(or in the case of equivalent bilateral symptoms, the
right foot), with the participant standing in a relaxed bi-
pedal stance position. All x-rays will be taken by the
same medical imaging department using a Shimadzu
UD150LRII 50 kw/30 kHz Generator and 0.6/1.2
P18DE-80S high speed x-ray tube from a ceiling sus-
pended tube mount. AGFA MD40 CR digital phosphor
plates in a 24 cm × 30 cm cassette will be used. The tube
will be angled 90 degrees and centred at the base of the
third metatarsal, with the film focus distance set at
100 cm. All radiographs will be examined by HBM, SEM
and JMT, to determine the presence of OA, using a
radiographic atlas of foot OA developed by our group
[55,56]. The reliability of assessments using this atlas
have been reported in detail previously (kappa values
greater than 0.76 [55]).
Treatment preference and credibility/expectation
In open randomised trials of musculoskeletal disorders, it
has been demonstrated that participants who are allocated
to their preferred treatment achieve better outcomes than
those who do not receive their preferred treatment, des-
pite the randomisation process resulting in equivalent
baseline outcome measure scores [57]. To address this
issue, participants will be asked if they have a preference
for either treatment (documented as rocker-sole shoes,
prefabricated foot orthoses or no preference), although
their response will not influence their randomised groupallocation [58]. This approach conserves all the advantages
of a fully randomised design but enables the interaction
between preference and outcomes to be quantified [59]. A
related issue is treatment credibility (participants’ beliefs
about the logic underpinning the intervention) and treat-
ment expectancy (participants’ perceptions of how much
they may benefit) [60]. To quantify this, the Credibility/
Expectancy Questionnaire (CEQ) [61] will be adminis-
tered after randomisation. The CEQ consists of six items:
three related to credibility and three related to expectancy.
For each item, participants will be asked to rate the cred-
ibility of the treatment and their expectations on a 9-point
Likert scale. High scores on the scale indicate that the par-
ticipant considers the treatment to be credible and expects
the treatment to be effective. The CEQ has been shown to
have good internal consistency and test-retest reliability
[61], and has recently been used to assess the credibility of
sham dry needling [62] and sham foot orthoses [63] used
in clinical trials.
Biomechanical evaluation
Because the proposed mechanism of action of the
rocker-sole shoes is a change in biomechanical function
of the lower limb, two approaches will be used to evalu-
ate their effects at the baseline appointment. First,
spatio-temporal parameters and three-dimensional mo-
tion of the thigh and lower leg during gait will be re-
corded using a wireless, wearable sensor motion analysis
system (LEGSys™, Biosensics, Boston, MA, USA). This
system consists of accelerometers and gyroscopes attached
with Velcro™ straps to each lower leg and thigh. The
method for calculation of the spatio-temporal parameters
of gait is described in detail elsewhere [64]. To summarise,
the gait phases are determined from the precise events of
heel-strike (initial foot contact) until toe-off (terminal foot
contact). These events are extracted from gyroscopes at-
tached to each shank through a local minimal peak detec-
tion scheme. Based on each participant’s height and using
a biomechanical model, spatial parameters (i.e. stride
length and stride velocity) and kinematics (knee and hip)
are estimated by integration of the angular rate of rotation
of the thigh and shank relative to the waist sensor. Gait
analysis with this system has been validated in healthy
controls [64], older people [65], and patients with hip
osteoarthritis [66]. After a familiarisation period, partici-
pants will complete 4 walking trials for each footwear con-
dition over an 8 metre distance. To exclude the effect of
acceleration and deceleration steps, only the middle four
steps from each trial will be included for analysis. An aver-
age recording will be determined from the 16 steps (4
steps from 4 trials) for each condition. Second, plantar
pressures (specifically, peak pressure under the hallux, first
MTPJ and lesser MTPJs) will be measured with the in-
shoe Pedar® system (Novel GmbH, Munich, Germany), a
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[67-69]. The Pedar® insoles are approximately 2 mm thick
and consist of 99 capacitive pressure sensors, arranged in
grid alignment. Plantar pressure data will be sampled at a
frequency of 50 Hz. Both groups will undergo the same
biomechanical assessment. However, for rocker-sole
shoe group, comparisons will be made between their
own shoes and the rocker-sole shoes, while in the pre-
fabricated foot orthoses group, comparisons will be
made when wearing their own shoes (with and without
the prefabricated orthoses).
Outcome measures
Primary and secondary outcome measures will be col-
lected at baseline and 4, 8 and 12 weeks. These time
points have been selected as 4 weeks is considered the
earliest time of greatest effect and 12 weeks is consid-
ered to be a standard clinical follow-up time [17,70]. To
avoid over-testing and to minimise the risk of Type I
error associated with serial measurements, statistical
analysis of the effectiveness of the interventions will spe-
cifically focus on the change in primary outcome mea-
sures between baseline and 12 weeks [71,72].
The primary outcome measure will be the foot pain
domain of the Foot Health Status Questionnaire (FHSQ)
[73]. The FHSQ is a foot-specific health-related quality
of life outcome measure consisting of 13 questions that
assess four domains of foot health including pain, func-
tion, footwear and general foot health. Questions within
each domain are scored using a Likert response format,
with an output score produced ranging from 0 to 100,
with a score of 100 indicating optimum foot health and a
score of 0 indicating very poor foot health. The FHSQ has
been shown to have a high degree of internal consistency
(Cronbach's α = 0.88) and test-retest reliability (intra-class
correlation coefficient = 0.86 [73]), and has been used in
several RCTs by our group [17,62,74]. A recent review rec-
ommended the use of the FHSQ in clinical trials of
rheumatological foot disorders [75]. Participants treated
for bilateral symptoms will be asked to describe symptoms
of their most painful foot. If both feet are equally painful,
the right foot will be selected as the index foot.
Secondary outcome measures will include:
(i) the function domain of the FHSQ, measured at
baseline, 4, 8 and 12 weeks;
(ii) the Foot Function Index - Revised (Short Form)
[76], measured at baseline and 12 weeks;
(iii) severity of pain at the first MTPJ while walking
over a flat surface and during rest over the last
week (each via a 100 mm visual analog scale
[VAS]), measured at baseline, 4, 8 and 12 weeks;
(iv) duration and severity of stiffness at the first MTPJ
after first awakening in the morning, during thelast week (via a 100 mm VAS), measured at
baseline, 4, 8 and 12 weeks;
(v) severity of stiffness after sitting, lying, or resting later
in the day, during the last week (via a 100 mm
VAS), measured at baseline, 4, 8 and 12 weeks;
(vi) global change in symptoms using a 15-point Likert
scale (The responses will range from "A very great
deal better" to "A very great deal worse") measured at
12 weeks;
(vii) health status (using the Short-Form-12 Version 2
questionnaire) [77], measured at baseline and
12 weeks;
(viii) use of paracetamol rescue medication (number of
participants and mean consumption) and
co-interventions to relieve pain at the first MTPJ,
documented with a monthly diary throughout the
12 week study period;
(ix) the frequency and type of self-reported adverse
events (such as falls and development of new pain
in other body regions), collected at 4 weekly inter-
vals throughout the 12 week study period;
(x) the Incidental and Planned Activity Questionnaire,
a self-report questionnaire that covers the frequency
and duration of several levels of planned and inci-
dental physical activity [78], measured at baseline
and 12 weeks.
To maximise response to the postal questionnaire out-
come measures, we will send a postcard reminder after
one week to non-responders, and then follow-up with
up to three attempted contacts by telephone and/or
email over a two week period.
Sample size
The sample size for the study has been determined
using an a priori power analysis based on the primary
outcome measure: the pain domain of the FHSQ [73].
We have previously determined that the minimal im-
portant difference for this measure in people with foot
pain is 13 points [79]. Using a standard deviation of
19 (derived from our recent trial [17]), a power level
of 0.8, alpha level of 0.05 and accounting for a drop-
out rate of 15%, a sample size of 80 participants (i.e.
approximately 40 per group) will be required. We have
conservatively ignored the extra precision provided by
covariate analysis when estimating the sample size, and
have conservatively selected a drop-out rate at the
higher end of previous trials of specialised footwear
and/or orthoses for lower limb OA (between 2 and
15%) [30,80-82].
Evaluation of adherence
Adherence to the intervention in both groups will be
documented at 4, 8 and 12 weeks. Participants will
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day and number of days they have worn their rocker-sole
shoes or prefabricated foot orthoses during the previous
4 weeks. To minimise participant burden, adherence will
be documented on the day with recall over the previous
4 weeks, rather than by daily diary entries.
Complications and adverse events
Complications and adverse events associated with the
intervention are unlikely. However, the questionnaires at
the 4, 8 and 12 week follow-ups will provide participants
with an opportunity to report any difficulties they have
with the interventions, and all adverse events will be re-
ported in the final manuscript.
Statistical analysis
Statistical analysis will be undertaken using SPSS® ver-
sion 21.0 (IBM Corp, NY, USA) using the intention-to-
treat principle for all randomised participants [38]. The
exception to this will be the safety outcome measures
which will be analysed as treated. In participants with bi-
lateral symptoms, the most painful foot will be analysed.
Multiple imputation will be used to replace any missing
data using five iterations, with age, baseline scores, and
group allocation as predictors [83]. The exception will
be for the variables use of rescue medication and co-
interventions where no data substitution will be applied.
Standard tests to assess continuous data for normal dis-
tribution will be used and transformation carried out if
required. Differences in the primary and secondary out-
come measures between the two groups will be com-
pared. Continuously-scored outcome measures will be
analysed using analysis of covariance with baseline
scores and intervention group entered as independent
variables [84]. Ordinal scaled data will be analysed
using non-parametric tests. Dichotomously-scored out-
come measures will be compared using relative risk,
risk difference and number needed to treat. For the gait
analysis component of the study, differences in bio-
mechanical variables will be compared using paired t-tests
and effect sizes (or in the case of non-normally distributed
data, medians will be compared using Mann–Whitney
U tests).
Discussion
The objective of this trial is to compare the effectiveness
of rocker-sole footwear and individualised prefabricated
foot orthoses in reducing pain associated with OA of the
first MTPJ. This will be the third clinical trial under-
taken for this condition and the first to focus on
footwear-related interventions. Our recent systematic re-
view of interventions for first MTPJ OA [15] revealed
only one low quality randomised trial evaluating the ef-
fectiveness of two different physical therapy programs in20 participants [16], and more recently, our group com-
pleted an RCT which found that intra-articular visco-
supplementation (hylan G-F20) was no more effective
than a placebo (sterile saline) [17]. As such, the trial will
provide novel and clinically relevant information to in-
form the non-surgical management of this common and
disabling condition.
The underlying biomechanical rationale for the use of
mechanical interventions for first MTPJ OA is that the
condition results from the inability of the first metatarsal
to plantarflex during propulsion to allow the proximal
phalanx to dorsally rotate on the first metatarsal head,
thereby resulting in dorsal joint compression of the first
MTPJ [12,31]. However, the two interventions to be
compared in this trial aim to address this biomechanical
deficit in different ways. Rocker-sole footwear is thought
to reduce the need for first MTPJ dorsiflexion during
propulsion, by enabling the body’s centre of mass to
“rollover” the base of support, thereby decreasing sagittal
plane motion of the ankle [19-22], forefoot [19] and first
MTPJ [24], and reducing forefoot plantar pressures
[22,23]. In contrast, foot orthoses with a first ray cut-
out, forefoot extension and medial wedging aim to limit
rearfoot pronation and facilitate first ray plantarflexion
during propulsion, thereby allowing the proximal phal-
anx to rotate on the first metatarsal head to achieve suf-
ficient first MTPJ dorsiflexion [31]. The available
evidence addressing this proposed mechanism of action
of foot orthoses, however, is equivocal. While two stud-
ies have reported increases in first MTPJ dorsiflexion
with orthoses placed under the foot in static stance
[85,86], one study reported no change in first MTPJ
dorsiflexion [87]. Gait studies have been similarly incon-
sistent, with two studies reporting a decrease in first
MTPJ dorsiflexion (with medial wedging [88] and orth-
oses [34]) and one study reporting no change [35].
The prefabricated orthoses in this study will be modi-
fied in a similar manner to the protocol described by
Welsh et al. [35]. However, there are two key differences
in the inclusion criteria between our two studies. In the
Welsh et al. study, participants were excluded if they
had an FPI score <4 or exhibited less than 40 degrees of
non-weightbearing first MTPJ dorsiflexion. This ap-
proach is based on three assumptions: (i) that people
with first MTPJ OA are more likely to have pronated
feet; (ii) that control of rearfoot pronation is an import-
ant goal of treatment for this condition, and; (iii) that in-
dividuals with less than 40 degrees of non-weightbearing
first MTPJ dorsiflexion would not benefit from the
orthoses. Participants in our trial will not be excluded
on the basis of foot posture, as our recent systematic re-
view did not find pronated foot posture to be strongly
associated with this condition [12]. Furthermore, the gait
analysis component of the Welsh et al. study found no
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gesting that control of rearfoot pronation did not con-
tribute to the observed improvement in symptoms.
Finally, participants in our trial will be required to have
less than 64 degrees of first MTPJ dorsiflexion (as we
have shown that this cut-off is associated with radio-
graphic OA in the first MTPJ [41]), but we will not ex-
clude any participants on the basis of having insufficient
range of motion in the first MTPJ. It could be argued
that individuals with very limited first MTPJ range of
motion have little to gain from prefabricated foot orth-
oses with a modification (a first ray cut-out) that, theor-
etically, facilitates motion at the first MTPJ by allowing
the first ray to plantarflex. However, this mechanism is
yet to be adequately demonstrated, and it is possible that
the orthoses could achieve beneficial therapeutic effects
through other mechanisms, such as reducing peak pres-
sure under the hallux and first MTPJ [85].
The gait analysis component of the study will provide
useful insights into the possible mechanism of action of
the interventions. The wearable sensor motion analysis
system (LEGSys™, Biosensics, Boston, MA, USA) pro-
vides high resolution temporal and kinematic data, with-
out the laboratory constraints and data processing
requirements of traditional motion analysis systems [89].
The use of this system will help identify changes in
lower limb function associated with the footwear and
orthoses (particularly changes in sagittal plane motion of
the shank and thigh), and whether these changes are re-
lated to improvement in symptoms. Similarly, the in-
shoe plantar pressure system (Pedar®, Novel GmbH,
Munich, Germany) will identify the extent to which the
high peak pressures under the hallux frequently ob-
served in individuals with first MTPJ OA [6,90] are miti-
gated by the interventions. It should be noted, however,
that it is not possible to measure first MTPJ motion dir-
ectly in this study, as this requires the permanent modi-
fication of the upper of the shoe to allow placement of
reflective markers or electromagnetic motion sensors on
the foot.
Participants will be reviewed at 4-weekly intervals up
to 12 weeks, which is similar to previous footwear trials
which have employed 8 week [91] or 12 week [29,30,92]
follow-up periods, and longer than the 4 week physical
therapy trial for first MTPJ OA by Shamus et al. [16].
Although our trial of viscosupplementation for first
MTPJ OA followed participants for 24 weeks, the effect
of treatment clearly plateaued at 12 weeks in both
groups [17]. We are therefore confident that the 12 week
duration of the trial is sufficient to detect differences be-
tween the groups, if they exist. Furthermore, 12 weeks is
considered to be a standard clinical follow-up period in
trials evaluating the effects of interventions for OA [70].
The trial will incorporate 4 repeated measurements forthe primary outcome measure (baseline, 4 weeks, 8 weeks
and 12 weeks) to provide insights into the trajectory of
any improvements in symptoms. However, to address the
issue of multiple testing of serial measurements [71,72],
we have pre-specified 12 weeks as the primary end-point,
and no statistical comparisons of the 4 and 8 week scores
will be undertaken.
There are three key limitations of the study design.
Firstly, this is not a controlled trial, as both groups will
receive an active intervention that has the potential to
be therapeutically beneficial. This was an ethical require-
ment of our institution, as our original proposal to in-
clude “sham” orthoses as the comparator [63] was
considered by the ethics committee to be withholding
“usual” care. Because usual care is not well documented
for this condition, we selected what we believe to be a
simple, commonly-used treatment (prefabricated foot
orthoses) with some evidence to support it, albeit it rela-
tively low quality (case series evidence) [35]. This change
in protocol unavoidably reduces the methodological
rigour of the trial, but also increases its external validity.
Secondly, due to the nature of the interventions, re-
search staff cannot be blinded to group allocation. How-
ever, follow-up assessment of outcome measures will be
via self-completion questionnaires returned by mail, and
research staff entering the data and conducting the ana-
lyses will be blinded to group allocation. Blinding partici-
pants in relation to the two treatments being offered was
considered (i.e. by referring to them as “two footwear-
related interventions” rather than specifying the rocker-
soled shoes and foot orthoses). However, the inherent
risk of this approach is that some participants may not
be prepared to the wear the rocker-soled shoes for aes-
thetic reasons (and some could withdraw from the
study immediately after being randomised for this rea-
son). On balance, we considered that the reduction in
methodological rigour created by poor adherence and
differential drop-out was probably greater than that
created by lack of blinding; hence our decision to
openly advise participants as to the two treatments be-
ing compared.
A third, related issue is that because we will openly
disclose the two treatments during the recruitment
process, there is some risk of “resentful demoralisation”
in participants who are allocated to the prefabricated
foot orthoses group. That is, some participants who are
allocated to receive the prefabricated foot orthoses may
be resentful of not receiving the more expensive and
(more visually substantial) rocker-soled shoe intervention,
which may affect their adherence to the tasks required of
them in the study and systematically influence their re-
sponses to the outcome measure questionnaires [58]. To
address this, we will document both participant preference
prior to randomisation and participants’ perceptions of
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This approach will not prevent resentful demoralisation,
but will enable post-randomisation effects of treatment
preference to be quantified, and if necessary, factored into
the analysis as a prognostic variable.
Trial status
This study will be the first randomised trial to compare
the effectiveness of rocker-sole footwear and individua-
lised prefabricated foot orthoses in reducing pain associ-
ated with osteoarthritis of the first MTPJ, and only the
third randomised trial conducted for this common and
disabling condition. Recruitment of participants will
commence in February 2014 and final results are ex-
pected to be available in June 2015.
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